HUP0101694A1 - Gyulladásos bélbetegségek kezelésére vagy megelőzésére szolgáló, hatóanyagként IL-6 antagonistát tartalmazó készítmény - Google Patents

Gyulladásos bélbetegségek kezelésére vagy megelőzésére szolgáló, hatóanyagként IL-6 antagonistát tartalmazó készítmény

Info

Publication number
HUP0101694A1
HUP0101694A1 HU0101694A HUP0101694A HUP0101694A1 HU P0101694 A1 HUP0101694 A1 HU P0101694A1 HU 0101694 A HU0101694 A HU 0101694A HU P0101694 A HUP0101694 A HU P0101694A HU P0101694 A1 HUP0101694 A1 HU P0101694A1
Authority
HU
Hungary
Prior art keywords
active ingredient
preventives
remedies
antagonists
intestinal diseases
Prior art date
Application number
HU0101694A
Other languages
English (en)
Inventor
Hiroaki Ito
Mitsunari Yamamoto
Tadamitsu Kishimoto
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Tadamitsu Kishimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13339502&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0101694(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Seiyaku Kabushiki Kaisha, Tadamitsu Kishimoto filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of HUP0101694A1 publication Critical patent/HUP0101694A1/hu
Publication of HUP0101694A3 publication Critical patent/HUP0101694A3/hu
Publication of HU225539B1 publication Critical patent/HU225539B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgyát gyulladásos bélbetegség, így például Crohn-betegség vagy colitis ulcerosa kezelésére vagy megelőzésére szolgáló,hatóanyagként valamely interleukin-6 (IL-6) antagonistát, így példáulegy IL-6 receptor ellenes antitestet tartalmazó készítmény képezi. Atalálmány további tárgyát képezi valamely interleukin-6 (IL-6)antagonista, így például az IL-6 receptor ellenes antitest alkalmazásagyulladásos bélbetegség, így például Crohn-betegség vagy colitisulcerosa kezelésére vagy megelőzésére szolgáló készítményelőállítására. Ó
HU0101694A 1998-03-17 1999-03-16 Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient antibody against il-6 receptor HU225539B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6725098 1998-03-17
PCT/JP1999/001298 WO1999047170A1 (fr) 1998-03-17 1999-03-16 Agents prophylactiques ou therapeutiques pour affections intestinales inflammatoires renfermant, comme ingredient actif, des antagonistes de il-6

Publications (3)

Publication Number Publication Date
HUP0101694A1 true HUP0101694A1 (hu) 2002-12-28
HUP0101694A3 HUP0101694A3 (en) 2003-08-28
HU225539B1 HU225539B1 (en) 2007-02-28

Family

ID=13339502

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101694A HU225539B1 (en) 1998-03-17 1999-03-16 Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient antibody against il-6 receptor

Country Status (19)

Country Link
US (2) US6723319B1 (hu)
EP (1) EP1074268B1 (hu)
JP (1) JP4124573B2 (hu)
KR (1) KR100407811B1 (hu)
CN (2) CN100374159C (hu)
AT (1) ATE383875T1 (hu)
AU (1) AU754006B2 (hu)
CA (1) CA2324115C (hu)
CZ (1) CZ297083B6 (hu)
DE (1) DE69937994T2 (hu)
DK (1) DK1074268T3 (hu)
ES (1) ES2299241T3 (hu)
HK (2) HK1033911A1 (hu)
HU (1) HU225539B1 (hu)
NO (1) NO327718B1 (hu)
PL (1) PL201461B1 (hu)
PT (1) PT1074268E (hu)
RU (1) RU2195960C2 (hu)
WO (1) WO1999047170A1 (hu)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
HU227708B1 (en) * 1994-10-21 2011-12-28 Chugai Pharmaceutical Co Ltd Use of anti-interleukin-6-receptor antibodies mr-16 and pm-1 and derivatives thereof for producing pharmaceutical preparation for treating diseases caused by il-6 production
ATE547119T1 (de) 1997-03-21 2012-03-15 Chugai Pharmaceutical Co Ltd Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
PL201461B1 (pl) * 1998-03-17 2009-04-30 Chugai Pharmaceutical Co Ltd Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny
EP1085906B1 (en) * 1998-06-10 2008-08-13 Ophidian Pharmaceuticals, Inc. Anti il6 antibodies in the prevention and treatment of inflammatory bowel disease
AU2000279625A1 (en) * 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
WO2003068259A1 (en) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
JP4463104B2 (ja) * 2002-08-30 2010-05-12 財団法人化学及血清療法研究所 ヒト抗ヒトインターロイキン−６抗体及び該抗体フラグメント
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005028514A1 (en) * 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg. Use of a compound for reducing the biological effectiveness of il-6
CN1874790B (zh) * 2003-10-17 2011-11-16 中外制药株式会社 间皮瘤治疗剂
US8617550B2 (en) * 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
EP3736295A1 (en) 2004-03-24 2020-11-11 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
JP5620626B2 (ja) * 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
BRPI0617378B8 (pt) * 2005-10-14 2022-09-20 Chugai Pharmaceutical Co Ltd Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) * 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
WO2007086490A1 (ja) * 2006-01-27 2007-08-02 Keio University 脈絡膜血管新生を伴う疾患の治療剤
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
DK3056568T3 (da) * 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
JP5754875B2 (ja) * 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
MX2009001110A (es) 2006-08-03 2009-05-11 Vaccinex Inc Anticuerpos monoclonales anti-il-6 y usos de los mismos.
CN101528778A (zh) * 2006-08-18 2009-09-09 埃博灵克斯股份有限公司 用于治疗与il-6-介导的信号传导相关的疾病和病症的针对il-6r的氨基酸序列以及包括其的多肽
WO2008065384A2 (en) * 2006-11-30 2008-06-05 Astrazeneca Ab Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor
JP2010095445A (ja) * 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
CA2675625C (en) 2007-01-23 2016-09-13 Shinshu University Chronic rejection inhibitor
MX2009008099A (es) 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) * 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
NZ597767A (en) * 2007-05-21 2013-06-28 Bristol Myers Squibb Co Antibodies to IL-6 and use thereof
MX2009012493A (es) * 2007-05-21 2010-01-20 Alder Biopharmaceuticals Inc Metodos de humanizacion de anticuerpo de conejo novedosos y anticuerpos de conejo humanizados.
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
SG193868A1 (en) * 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
CL2008002885A1 (es) * 2007-09-26 2010-07-02 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende
JP5334319B2 (ja) * 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
CN101939424B (zh) * 2007-12-05 2016-12-28 中外制药株式会社 抗nr10抗体及其应用
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP3521311A1 (en) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2297202B1 (en) * 2008-05-13 2016-01-13 NovImmune SA Anti-il-6/il-6r antibodies and methods of use thereof
CA2728243C (en) * 2008-06-05 2020-03-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
AU2010208125B2 (en) * 2009-01-29 2015-02-12 Medimmune, Llc Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
WO2010106436A2 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Novel anti-inflammatory agents
TWI544077B (zh) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
SI2421533T1 (sl) 2009-04-22 2019-01-31 Resverlogix Corp. Nova protivnetna sredstva
SG176074A1 (en) 2009-05-15 2011-12-29 Chugai Pharmaceutical Co Ltd Anti-axl antibody
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
KR101436219B1 (ko) 2009-10-26 2014-09-01 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066369A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to raise albumin and/or lower crp
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2578233B1 (en) 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
ES2932398T3 (es) 2010-05-28 2023-01-18 Chugai Pharmaceutical Co Ltd Potenciador de la respuesta de las células T antitumorales
EP2787007A3 (en) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subcutaneously administered ANTI-IL-6 receptor antibody
WO2012071561A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
RU2642318C2 (ru) 2010-11-30 2018-01-24 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
MD480Z5 (ro) * 2011-07-07 2012-09-30 Эльвира АНДОН Metodă de tratament al colitei ulceroase nespecifice acute
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
CN104169299B (zh) 2012-01-23 2018-06-05 瑞泽恩制药公司 含抗Ang-2 抗体的稳定化制剂
CN104349787B (zh) 2012-05-21 2019-02-15 韩国生命工学研究院 含有荔枝草提取物或其馏分作为活性成分的预防或治疗stat-3介导疾病的药物组合物
SG11201501924UA (en) * 2012-09-13 2015-05-28 Chugai Pharmaceutical Co Ltd Gene knock-in non-human animal
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015116852A1 (en) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
EP3299810B1 (en) 2015-05-19 2021-07-07 National Center of Neurology and Psychiatry Method for determining application of novel therapy to multiple sclerosis (ms) patient
WO2016195088A1 (ja) 2015-06-04 2016-12-08 国立研究開発法人 国立精神・神経医療研究センター Ｉｌ－６阻害剤を有効成分とする精神疾患治療剤
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
BR112018009312A8 (pt) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd método para promover eficiência de purificação de polipeptídeo contendo região de fc
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP7182162B2 (ja) 2017-01-27 2022-12-02 株式会社ステムリム 心筋症、陳旧性心筋梗塞および慢性心不全の治療薬
SG11201906852XA (en) 2017-02-01 2019-08-27 Univ Yale Treatment of diuretic resistance
WO2018170405A1 (en) 2017-03-17 2018-09-20 Ohio State Innovation Foundation Nanoparticles for delivery of chemopreventive agents
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
PE20211196A1 (es) 2018-01-05 2021-07-01 Novo Nordisk As Metodos para tratar inflamacion mediada por il-6 sin inmunosupresion
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
CN114206442A (zh) 2019-01-31 2022-03-18 赛诺菲生物技术公司 用于治疗幼年特发性关节炎的抗il-6受体抗体
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2021136841A2 (fr) * 2019-12-31 2021-07-08 Peptinov Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires
WO2022047730A1 (en) * 2020-09-04 2022-03-10 Shanghai Pharmaceuticals Holding Co., Ltd. Methods to treat inflammatory bowel disease
GB202301306D0 (en) * 2023-01-30 2023-03-15 Ucl Business Ltd Treatment of granulomatous disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US6428979B1 (en) 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2914672B2 (ja) 1989-01-17 1999-07-05 中外製薬株式会社 Ｂｓｆ▲下２▼アンタゴニスト
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5210075A (en) 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
PT97124A (pt) 1990-03-23 1991-12-31 Gist Brocades Nv Processo para a prparacao de composicoes inibidoras de interleucina - 6 (il-6)
DK0628639T3 (da) 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1995009873A1 (en) 1993-10-06 1995-04-13 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
JPH07324097A (ja) 1994-05-30 1995-12-12 Daicel Chem Ind Ltd インターロイキン６拮抗剤、及びペプチド類または医薬として許容されるその塩類
CA2191733A1 (en) 1994-06-07 1995-12-21 Daniel A. Vallera Methods for inhibiting antigen specific t cell responses
EP0766564A4 (en) 1994-06-24 1998-09-23 Immunex Corp SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
JPH0850829A (ja) 1994-08-05 1996-02-20 Tokai Rika Co Ltd レバースイッチ
US6010871A (en) 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein
ES2384222T3 (es) 1994-10-07 2012-07-02 Chugai Seiyaku Kabushiki Kaisha Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo
HU227708B1 (en) 1994-10-21 2011-12-28 Chugai Pharmaceutical Co Ltd Use of anti-interleukin-6-receptor antibodies mr-16 and pm-1 and derivatives thereof for producing pharmaceutical preparation for treating diseases caused by il-6 production
JPH08245414A (ja) * 1995-01-27 1996-09-24 Private Biolog Corp Ｉｌ−６関連疾患の治療用組成物および方法
US5569680A (en) * 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
US6261560B1 (en) * 1995-02-13 2001-07-17 Chugai Seiyaku Kabushiki Kaisha Method for inhibiting muscle protein proteolysis with antibodies to interleukin-6 receptor
JPH08311098A (ja) 1995-05-22 1996-11-26 Daicel Chem Ind Ltd 新規ペプチド類およびそれを含有するインターロイキン６拮抗剤
US5571513A (en) 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
WO1996040966A1 (en) 1995-06-07 1996-12-19 Private Biologicals Corporation Compositions and methods of treating il-6 associated diseases
JPH09235276A (ja) * 1995-12-27 1997-09-09 Takeda Chem Ind Ltd オキサゾール誘導体、その製造法および用途
AU1209497A (en) 1995-12-27 1997-07-28 Takeda Chemical Industries Ltd. Oxazole derivatives, their production and use
CA2251355C (en) * 1996-04-09 2009-06-09 Applied Research Systems Ars Holding N.V. Il-6 mutein
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
PL201461B1 (pl) * 1998-03-17 2009-04-30 Chugai Pharmaceutical Co Ltd Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny
EP1085906B1 (en) * 1998-06-10 2008-08-13 Ophidian Pharmaceuticals, Inc. Anti il6 antibodies in the prevention and treatment of inflammatory bowel disease
AU2000279625A1 (en) 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
RU2285527C2 (ru) 2002-04-12 2006-10-20 Пфайзер Инк. Использование лигандов рецептора ер4 для лечения опосредованных il-6 заболеваний
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases

Also Published As

Publication number Publication date
DE69937994T2 (de) 2008-12-24
DK1074268T3 (da) 2008-04-28
NO20004581L (no) 2000-11-10
ATE383875T1 (de) 2008-02-15
DE69937994D1 (de) 2008-03-06
WO1999047170A1 (fr) 1999-09-23
HUP0101694A3 (en) 2003-08-28
PL201461B1 (pl) 2009-04-30
PT1074268E (pt) 2008-02-28
JP4124573B2 (ja) 2008-07-23
HK1036018A1 (en) 2001-12-21
CA2324115C (en) 2008-12-23
CN1297357A (zh) 2001-05-30
AU754006B2 (en) 2002-10-31
CA2324115A1 (en) 1999-09-23
NO327718B1 (no) 2009-09-14
US20040071706A1 (en) 2004-04-15
RU2195960C2 (ru) 2003-01-10
CN101239185A (zh) 2008-08-13
CZ20003297A3 (cs) 2001-02-14
US6723319B1 (en) 2004-04-20
KR20010041933A (ko) 2001-05-25
NO20004581D0 (no) 2000-09-14
EP1074268A4 (en) 2002-11-20
PL342938A1 (en) 2001-07-16
ES2299241T3 (es) 2008-05-16
KR100407811B1 (ko) 2003-12-01
CZ297083B6 (cs) 2006-09-13
HK1033911A1 (en) 2001-10-05
US7824674B2 (en) 2010-11-02
EP1074268A1 (en) 2001-02-07
CN100374159C (zh) 2008-03-12
HU225539B1 (en) 2007-02-28
AU2748199A (en) 1999-10-11
EP1074268B1 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
HUP0101694A1 (hu) Gyulladásos bélbetegségek kezelésére vagy megelőzésére szolgáló, hatóanyagként IL-6 antagonistát tartalmazó készítmény
NO995006D0 (no) Nye forbindelser
BRPI0409910A (pt) métodos para o tratamento de doenças relacionadas com interleucina-6
EA200000299A1 (ru) Лекарства
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
HUP0101411A2 (hu) 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása
HUP0104318A2 (hu) cGMP PDE-5 inhibitort tartalmazó szabályzottan hatóanyagot felszabadító gyógyászati készítmények
HUP0203028A2 (hu) Tolterodint tartalmazó gyógyszerkészítmény és alkalmazása
MA26757A1 (fr) Preparation pharmaceutique de moxifloxacine
CY1106763T1 (el) Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου
HUP0104647A2 (hu) Hatóanyagként tilidin-mezilátot tartalmazó, szabályozott hatóanyag-leadású gyógyszerkészítmény
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
HUP0402358A2 (hu) Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására
IL154358A0 (en) Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
ATE180405T1 (de) Arzneimittel enthaltend einen quisqualat-rezeptor-antagonisten und einen dopamin-agonisten zur behandlung des morbus parkinson
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
HUP0400528A2 (hu) Neuropeptidáz Y inhibitor alkalmazása férfiak szexuális funkciózavarának kezelésére alkalmas gyógyszerkészítmény előállítására
HUP0401967A2 (hu) Nikotinsav-acetilkolin-receptor-agonisták alkalmazása nyugtalan láb szindróma kezelésére alkalmas gyógyszerkészítmények előállítására
HUP0303181A2 (hu) 4-Foszfodiészteráz típusú inhibitorok alkalmazása miokardiális betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
EA200100876A3 (ru) Фармацевтическая композиция для предупреждения или лечения заболевания, связанного с избыточным продуцированием il-12
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
IL124730A (en) Compositions for the treatment of gastrointestinal disorders comprising a bismuth compound and one or more antimicrobials, and the use of bismuth and an antimicrobial compound for the preparation of such compositions
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor
DE69618617D1 (de) Wismuth enthaltende zusammensetzungen zur verhütung und behandlung gastrointestinaler beschwerden
TNSN05084A1 (fr) Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees